Analysts’ Recommendations for Pfizer in March 2018


Mar. 19 2018, Updated 7:31 a.m. ET

Analysts’ estimates

Pfizer (PFE) surpassed Wall Street analysts’ consensus estimate for EPS (earnings per share) in 4Q17, reporting EPS of $0.62 compared to the estimate of $0.56. 

However, Pfizer missed analysts’ consensus revenue estimate, reporting revenue of ~$13.70 billion compared to the estimate of ~$13.72 billion in the quarter.

The above chart shows analysts’ recommendations on Pfizer stock over the last 12 months. For 1Q18, Wall Street analysts expect the company’s revenue to rise ~2.1% to $13.1 billion compared to ~$12.8 billion in 1Q17. Analysts expect Pfizer to report EPS of $0.73 in 1Q18 compared to $0.69 in 1Q17.

Article continues below advertisement

Analysts’ ratings

Pfizer’s stock price has risen nearly 6.2% over the last 12 months, and it’s risen ~0.4% year-to-date in 2018. Analysts’ estimates show that the stock has the potential to return ~10.5% over the next 12 months. Their recommendations show a 12-month target price of $40.15 per share for the stock compared to its last price of $36.35 on March 14, 2018.

Analysts’ recommendations

As of March 15, 2018, there are 23 analysts tracking Pfizer. Of these 23 analysts, 12 have recommended “buys” on the stock, nine have recommended “holds” on the stock, and two have recommended “sells.” The consensus rating for Pfizer stands at 2.57, which represents a moderate “buy” for value investors. Changes in analysts’ estimates and recommendations are based on company performance and changing trends in a stock’s price.

The VanEck Vectors Pharmaceutical ETF (PPH) has 5.0% of its total holdings in Pfizer, 4.9% in Merck & Co. (MRK), 5.2% in Bristol-Myers Squibb (BMY), and 5.8% in Teva Pharmaceuticals (TEVA).


Latest Teva Pharmaceutical Industries Ltd News and Updates

    Market Realist Logo

    © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.